| Page 50 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

Allogeneic Hematopoietic Cell Transplantation and Other Expensive Cellular Therapies: A Miracle for the Few but Off Limits to Many?

The number of patients undergoing allogeneic hematopoietic cell transplantation (HCT) for treatment of malignant and nonmalignant disorders has continued to grow worldwide. (footnotes) Great progress has been made in overcoming HLA/immunologic barriers, but nondonor barriers to HCT persist.(footnote) This represents a major unmet need because HCT is not accessible to everyone who would benefit from it.(footnote)

Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents

Author(s): 
Zeidan AM, Hu X, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Bewersdorf JP, Podoltsev NA, Gore SD, Ma X, Davidoff AJ
Primary Author: 
Zeidan AM
Journal Title: 
Leukemia & Lymphoma
Original Publication Date: 
Oct 2019

Population level survival of patients with

Bone Marrow Disease(s): 

DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes

Author(s): 
Reilly B, Tanaka TN, Diep D, Yeerna H, Tamayo P, Zhang K, Bejar R
Primary Author: 
Reilly B
Journal Title: 
Blood Advances
Original Publication Date: 
Oct 2019

Recurrent mutations implicate several epigenetic regulators in the early molecular pathobiology of

Bone Marrow Disease(s): 

The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion

Author(s): 
Park S, Kelaidi C, Meunier M, Casadevall N, Gerds AT, Platzbecker U
Primary Author: 
Park S
Journal Title: 
Annals of Hematology
Original Publication Date: 
Oct 2019

Bone Marrow Disease(s): 

Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence

Author(s): 
Nazha A, Sekeres MA, Bejar R, Rauh MJ, Othus M, Komrokji RS, Barnard J, Hilton CB, Kerr CM, Steensma DP, DeZern A, Roboz G, Garcia-Manero G, Erba H, Ebert BL, Maciejewski JP
Primary Author: 
Nazha A
Journal Title: 
JCO Precision Oncology
Original Publication Date: 
Sep 2019

PURPOSE:

Bone Marrow Disease(s): 

Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes

Author(s): 
Madan V, Li J, Zhou S, Teoh WW, Han L, Meggendorfer M, Malcovati L, Cazzola M, Ogawa S, Haferlach T, Yang H, Koeffler HP
Primary Author: 
Madan V
Journal Title: 
American Journal of Hematology
Original Publication Date: 
Nov 2019

Bone Marrow Disease(s): 

Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years

Author(s): 
Sheth VS, Potter V, Gandhi SA, Kulasekararaj AG, de Lavallade H, Muus P, Pagliuca A, Rice CFM, Mehra V, Grimaldi F, Inam S, Barber LD, Mufti GJ, Marsh JC
Primary Author: 
Sheth VS
Journal Title: 
Blood Advances
Original Publication Date: 
Oct 2019

Survival after allogeneic hematopoietic cell transplantation (HSCT) for severe

Bone Marrow Disease(s):